Setback

FDA approves mFlusiva, first mRNA flu vaccine

The FDA approved mFlusiva for ages 50+ — the first mRNA flu vaccine — after a unanimous June VRBPAC vote. The agency had refused to review the application in February under Prasad’s CBER, then reversed after his departure. A setback for the team’s anti-mRNA wing; a data point for the ‘plausible mechanism’ reformers who stayed.

Sources: CNN; Harvard Health

The Weekly Scoreboard

Every Friday: what the RFK Jr. HHS team did this week — wins, setbacks, warnings — sourced and linked. Free.

One email a week. No spam. Unsubscribe anytime. · Follow on Facebook

The Network — One Publisher, Every Front
Published by Bowman Web Services.